


Key indicators of environmental performance




Emissions to air			
Acidification potential		Tons SO ₂ -equivalents	361
Global warming potential	1,000 tons	CO ₂ -equivalents	155
Ozone-depleting potential		Kg CFC ₁₁ -equivalents	43
Organic solvents		Tons	140



Consumption

Raw materials	1,000 tons	102
Packaging materials	1,000 tons	8
Water	1,000 m ³	2,621
Energy	1,000 GJ	2,299



Production

Turnover	DKK million	26,541
----------	-------------	--------



Distribution

Intermediary and final products are distributed to production facilities, affiliates and customers worldwide, primarily by lorry and air transport.



Waste

Liquid waste total	1,000 m ³	2,350	Solid waste total	Tons	21,356
Discharged to wastewater treatment	%	92	Recycled	%	41
Recycled as yeast cream	%	5	Incinerated	%	15
Recycled as fertiliser	%	3	Landfilled	%	9
			Controlled destruction	%	35

Key environmental impacts in the value chain



Research and development

Research and development of pharmaceuticals and delivery devices:

- Contained use of gene technology for research.
- Minor use of materials, water and energy.
- Discharge of wastewater.
- Minor disposal of solid waste.



Bulk production

Fermentation, recovery and purification of active pharmaceutical ingredients:

- Contained use of gene technology for production.
- Major use of materials, water and energy.
- Large-scale discharge of wastewater and other liquid wastes.
- Disposal of solid waste.
- Emission of solvents to air.



Finished goods production

Production of delivery devices, formulation, filling and packaging of pharmaceuticals:

- Use of materials, water and energy.
- Disposal of solid waste.
- Discharge of wastewater.



Distribution

Shipping and transport of intermediary and final products:

- Fuel for transport.

Our use of gene technology

Novo Nordisk uses gene technology and genetically modified organisms (GMOs) in biomedical research and the production of pharmaceuticals. We believe gene technology can help solve many of today's health issues and allow us to provide products in sufficient quantity or quality. Yet we recognise that use of this technology causes concerns. We take every precaution to ensure the safe use of GMOs. The GMOs we use for production are in the lowest risk category with no known risks to humans or the environment. All GMOs are handled under closed or contained conditions. The final products do not contain GMOs. We recognise the concern about the level of antibiotic resistance among microorganisms in the environment. Therefore, new production strains will be without antibiotic resistance genes whenever technically possible and practically feasible. No damage to human health or the environment has ever been recorded in our use of GMOs for research and production.